Evolution and molecular characterization of macrolide-resistant Streptococcus pneumoniae in Canada between 1998 and 2008

Journal of Antimicrobial Chemotherapy

Volumn 69, Issue 1, 2014, Pages 59-66

  Wierzbowski, Aleksandra K ^a   Karlowsky, James A ^a,b   Adam, Heather J ^a,b   Nichol, Kim A ^b   Hoban, Daryl J ^a,b   Zhanel, George G ^a,b  

^a UNIVERSITY OF MANITOBA   (Canada)

^b HEALTH SCIENCES CENTRE   (Canada)

Author keywords

Pili; Serotypes; Surveillance; Vaccines

Indexed keywords

CLINDAMYCIN; COTRIMOXAZOLE; DOXYCYCLINE; ERYTHROMYCIN; PENICILLIN G; PNEUMOCOCCUS VACCINE;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENE; BACTERIUM ISOLATE; BROTH DILUTION; CANADA; CONTROLLED STUDY; HOSPITAL LABORATORY; MULTIDRUG RESISTANCE; NONHUMAN; PREVALENCE; SEROTYPE; SEROTYPING; STREPTOCOCCUS PNEUMONIAE;

PILI; SEROTYPES; SURVEILLANCE; VACCINES;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; CANADA; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE, BACTERIAL; ELECTROPHORESIS, GEL, PULSED-FIELD; EVOLUTION, MOLECULAR; FEMALE; GENOTYPE; HUMANS; INFANT; INFANT, NEWBORN; MACROLIDES; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MOLECULAR TYPING; PNEUMOCOCCAL INFECTIONS; SEROTYPING; STREPTOCOCCUS PNEUMONIAE; VIRULENCE FACTORS; YOUNG ADULT;

EID: 84890407241     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkt332     Document Type: Article

References (33)

1. File TM Jr. Streptococcus pneumoniae and community-acquired pneumonia: a cause for concern. Am J Med 2004; 117 Suppl 3A: 39S-50S.
2. Mandell LA, Wunderink RG, Anzueto A et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007; 44 Suppl 2: S27-72.
3. Jacobs MR. Clinical significance of antimicrobial resistance in Streptococcus pneumoniae. S Afr Med J 2007; 97: 1133-40.
4. Lynch JP 3rd, Zhanel GG. Streptococcus pneumoniae: does antimicrobial resistance matter?. Semin Respir Crit Care Med 2009; 30: 210-38.
5. Wierzbowski AK, Nichol K, Laing N et al. Macrolide resistance mechanisms among Streptococcus pneumoniae isolated over 6 years of Canadian Respiratory Organism Susceptibility Study (CROSS) (1998 2004). J Antimicrob Chemother 2007; 60: 733-40.
6. Dipersio LP, Dipersio JR, Beach JA et al. Rise of Streptococcus pneumoniae isolates containing both erm(B) and mef(E) genes from an adult tertiary care community hospital system. Diagn Microbiol Infect Dis 2006; 55: 327-31.
7. Farrell DJ, Morrissey I, Bakker S et al. Molecular epidemiology of multiresistant Streptococcus pneumoniae with both erm(B)- and mef(A)- mediatedmacrolide resistance. J ClinMicrobiol 2004; 42: 764-8.
8. Moore MR, Gertz RE Jr, Woodbury RL et al. Population snapshot of emergent Streptococcus pneumoniae serotype 19A in the United States, 2005. J Infect Dis 2008; 197: 1016-27.
9. Reinert R, Jacobs MR, Kaplan SL. Pneumococcal disease caused by serotype 19A: review of the literature and implications for future vaccine development. Vaccine 2010; 28: 4249-59.
10. Hathaway LJ, Battig P, Muhlemann K. In vitro expression of the first capsule gene of Streptococcus pneumoniae, cpsA, is associated with serotype-specific colonization prevalence and invasiveness. Microbiology 2007; 153: 2465-71.
11. Dagan R. Impact of pneumococcal conjugate vaccine on infections caused by antibiotic-resistant Streptococcus pneumoniae. Clin Microbiol Infect 2009; 15 Suppl 3: 16-20.
12. HausdorffWP, Bryant J, Paradiso PR et al. Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, part I. Clin Infect Dis 2000; 30: 100-21.
13. Farrell DJ, Klugman KP, PichicheroM. Increased antimicrobial resistance among nonvaccine serotypes of Streptococcus pneumoniae in the pediatric population after the introduction of 7-valent pneumococcal vaccine in the United States. Pediatr Infect Dis J 2007; 26: 123-8.
14. Adam HJ, Karlowsky JA, Nichol KA et al. Baseline epidemiology of Streptococcus pneumoniae serotypes in Canada prior to the introduction of the 13-valent pneumococcal vaccine. Microb Drug Resist 2012; 18: 176-82.
15. Zahner D, Gudlavalleti A, Stephens DS. Increase in pilus islet 2-encoded pili among Streptococcus pneumoniae isolates, Atlanta, Georgia, USA. Emerg Infect Dis 2010; 16: 955-62.
16. Zhanel GG, Palatnick L, Nichol KA et al. Antimicrobial resistance in respiratory tract Streptococcus pneumoniae isolates: results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002. Antimicrob Agents Chemother 2003; 47: 1867-74.
17. Zhanel GG, AdamHJ, LowDE et al. Antimicrobial susceptibility of 15,644 pathogens from Canadian hospitals: results of the CANWARD 2007-2009 study. Diagn Microbiol Infect Dis; 2011; 69: 291-306.
18. Clinical and Laboratory Standards Institute. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically- Eighth Edition: Approved Standard M07-A8. CLSI, Wayne, PA, USA, 2009.
19. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Twenty-first Informational Supplement M100-S21. CLSI, Wayne, PA, USA, 2011.
20. Austrain R. TheQuellung reaction, a neglected microbiologic technique. J Med 1976; 43: 699-702.
21. Demczuk WH, Martin I, Griffith A et al. Serotype distribution of invasive Streptococcus pneumoniae in Canada during the introduction of the 13-valent pneumococcal conjugate vaccine, 2010. Can J Microbiol 2012; 58: 1008-17.
22. Bergman M, Huikko S, Huovinen P et al. Macrolide and azithromycin use are linked to increased macrolide resistance in Streptococcus pneumoniae. Antimicrob Agents Chemother 2006; 50: 3646-50.
23. Karlowsky JA, Lagace-Wiens PR, Low DE et al. Annual macrolide prescription rates and the emergence of macrolide resistance among Streptococcus pneumoniae in Canada from 1995 to 2005. Int J Antimicrob Agents 2009; 34: 375-9.
24. Farrell DJ, File TM, Jenkins SG. Prevalence and antibacterial susceptibility of mef(A)-positive macrolide-resistant Streptococcus pneumoniae over 4 years (2000 to 2004) of the PROTEKT US Study. J Clin Microbiol 2007; 45: 290-3.
25. Zhanel GG, DeCorby M, Noreddin A et al. Pharmacodynamic activity of azithromycin against macrolide-susceptible and -resistant Streptococcus pneumoniae simulating clinically achievable free serum, epithelial lining fluid and middle ear fluid concentrations. J Antimicrob Chemother 2003; 52: 83-8.
26. Brueggemann AB, Pai R, Crook DWet al. Vaccine escape recombinants emerge after pneumococcal vaccination in the United States. PLoS Pathog 2007; 3: e168.
27. Pillai DR, Shahinas D, Buzina A et al. Genome-wide dissection of globally emergent multi-drug resistant serotype 19A Streptococcus pneumoniae. BMC Genomics 2009; 10: 642.
28. Eskola J. Immunogenicity of pneumococcal conjugate vaccines. Pediatr Infect Dis J 2000; 19: 388-93.
29. NahmMH, Lin J, Finkelstein JAet al. Increase intheprevalence of thenewly discovered pneumococcal serotype 6C in the nasopharynx after introduction of pneumococcal conjugate vaccine. J Infect Dis 2009; 199: 320-5.
30. Park IH, Moore MR, Treanor JJ et al. Differential effects of pneumococcal vaccines against serotypes 6A and 6C. J Infect Dis 2008; 198: 1818-22.
31. Jacobs MR, Good CE, Bajaksouzian S et al. Emergence of Streptococcus pneumoniae serotypes 19A, 6C, and 22F and serogroup 15 in Cleveland, Ohio, in relation to introduction of the protein-conjugated pneumococcal vaccine. Clin Infect Dis 2008; 47: 1388-95.
32. Aguiar SI, Brito MJ, Goncalo-Marques J et al. Serotypes 1, 7F and 19A became the leading causes of pediatric invasive pneumococcal infections in Portugal after 7 years of heptavalent conjugate vaccine use. Vaccine 2010; 28: 5167-73.
33. LambertsenLM, HarboeZB, KonradsenHBet al. Non-invasiveerythromycinresistant pneumococcal isolates are more often non-susceptible to more antimicrobial agents than invasive isolates. Int J Antimicrob Agents 2010; 35: 72-5.